BB Biotech AGXSWX:BION +1.32%34 5-Year Yield-on-Cost % is 2.17 as of Jul. 03, 2026, which is 8% below its 10-year median of 2.35. GuruFocus rates XSWX:BION with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, BB Biotech AG ranks better than 57.52% on this metric.
BB Biotech AG's yield on cost for the quarter that ended in Mar. 2026 was 2.17.
The historical rank and industry rank for BB Biotech AG's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:BION'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.72 Med: 2.35 Max: 3.73
Current: 2.17
During the past 13 years, BB Biotech AG's highest Yield on Cost was 3.73. The lowest was 1.72. And the median was 2.35.
XSWX:BION's 5-Year Yield-on-Cost % is ranked better than 57.52% of 153
companies
in the Biotechnology industry
Industry Median: 1.72
vs XSWX:BION: 2.17
BB Biotech AG (XSWX:BION) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
BB Biotech AG 5-Year Yield-on-Cost % Related Terms
XSWX:BION vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, BB Biotech AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of BB Biotech AG is calculated as
BB Biotech AG (XSWX:BION) has a 5-Year Yield-on-Cost % of 2.17 as of Jul. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BB Biotech AG and its competitors. This is near median its historical median of 2.35. Over the past decade, BB Biotech AG's 5-Year Yield-on-Cost % has ranged from 1.72 to 3.73. According to the industry distribution chart, BB Biotech AG ranks #65 out of 153 companies in the Biotechnology industry, placing it in the top 42.5%.
Is BB Biotech AG's 5-Year Yield-on-Cost % too high?
BB Biotech AG's current 5-Year Yield-on-Cost % of 2.17 is near median its 10-year median of 2.35. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 3.73. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.72. BB Biotech AG's value of 2.17 is 26.2% above this industry median. Based on the distribution chart, BB Biotech AG ranks #65 out of 153 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BB Biotech AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #65 out of 153 companies for 5-Year Yield-on-Cost %. This puts BB Biotech AG in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.72. BB Biotech AG's value of 2.17 is 26.2% above this benchmark. Historically, BB Biotech AG's own 5-Year Yield-on-Cost % has ranged from 1.72 to 3.73 over the past decade. While the company's 10-year median is 2.35 vs. the industry median of 1.72, BB Biotech AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.72, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BB Biotech AG's current 5-Year Yield-on-Cost % of 2.17 is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BB Biotech AG and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current 5-Year Yield-on-Cost % is 2.17, which is near median its own 10-year median of 2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current 5-Year Yield-on-Cost % of 2.17. The current 5-Year Yield-on-Cost % is 2.17, which is near median its 10-year median of 2.35 and 26.2% above the Biotechnology industry median of 1.72. BB Biotech AG's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current 5-Year Yield-on-Cost % is 2.17 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
34GF Score
Get the complete analysis for XSWX:BION
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 